August 17, 2016 / 11:27 AM / a year ago

BRIEF-Trillium Therapeutics' TTI-621 receives FDA clearance to proceed in clinical trial

1 Min Read

Aug 17 (Reuters) - Trillium Therapeutics Inc

* Trillium Therapeutics receives FDA clearance to proceed with TTI-621 in clinical trial targeting solid tumors and mycosis fungoides Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below